title: [Psychiatric and Social Aspects of Patients with Fragile X Syndrome].
abstract: OBJECTIVE
  The goal of the study was to describe the burden of psychosocial risks, of mental illnesses and the ways of treatment of patients with fragile X syndrome (FRX).
  
  
  METHODS
  Data from a sample of 46 FRX-patients stemming from a prospective multicenter (N = 12) registry study (EXPLAIN) were analyzed with regard to psychosocial burden and treatment.
  
  
  RESULTS
  More than 50 % of all participants reported about relatives suffering from FRX, too. The majority of participants did not finish school and was suffering from one or another kind of mental problems. Younger participants (< 18 yrs.) tended to suffer from expansive disorders. Older participants were rather burdened by internalizing symptoms and disorders. Disorders were usually treated by psychotropic drugs added by logopedic therapies and occupational therapies (more than once a month). In our sample 90.6 % of younger and more than 64.3 % of older patients were still living with their parents.
  
  
  CONCLUSIONS
  Patients with FRX often suffer from additional mental disorders and should be diagnosed and treated early.
authors: Institut für Klinische Pharmakologie. Medizinische Fakultät, Technische Universität Carl Gustav Carus Dresden.
authors: David
authors: D
authors: Pittrow
authors: Abt. Psychiatrische Therapie für Menschen mit Geistiger Behinderung, Isar Amper Klinikum gGmbH, Klinikum München Ost, Haar.
authors: Franziska
authors: F
authors: Gaese
authors: Experimental and Clinical Research, Charité, Campus Berlin-Buch, Klinik für Psychiatrie und Psychotherapie, Charité, Campus Berlin-Mitte.
authors: Michael
authors: M
authors: Colla
authors: Rheinhessen Fachklinik Mainz, Kinder- und Jugendpsychiatrie, Mainz.
authors: Michael
authors: M
authors: Huss
authors: Zentrum für Kinder- und Jugendmedizin, Sozialpädiatrisches Zentrum, Städtisches Krankenhaus Dresden-Neustadt.
authors: Christoph
authors: C
authors: Kretschmar
authors: Medizinische Abteilung Novartis Pharma GmbH, Nürnberg.
authors: Marc
authors: M
authors: Brinkman
authors: Zentrum für Kinderneurologie und Sozialpädiatrie, Rheinhessen Fachklinik Mainz.
authors: Helmut
authors: H
authors: Peters
authors: Berliner Behandlungszentrum der Abteilung für Psychiatrie, Psychotherapie und Psychosomatik, Evangelisches Krankenhaus Königin Elisabeth Herzberge GmbH, Berlin.
authors: Samuel
authors: S
authors: Elstner
authors: Klinik für Psychiatrie, Neurologie, Psychosomatik und Psychotherapie im Kindes- und Jugendalter der Universitätsmedizin Rostock.
authors: Steffen
authors: S
authors: Weirich
authors: Klinik für Psychiatrie, Neurologie, Psychosomatik und Psychotherapie im Kindes- und Jugendalter der Universitätsmedizin Rostock.
authors: Frank
authors: F
authors: Häßler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D017281:Cost of Illness; D005260:Female; D005600:Fragile X Syndrome / Q000175:diagnosis / Q000235:genetics / Q000523:psychology* / Q000628:therapy; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005858:Germany; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000235:genetics / Q000523:psychology* / Q000628:therapy; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000235:genetics / Q000523:psychology* / Q000628:therapy; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D055815:Young Adult